Skip to main content
. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6

Fig. 2.

Fig. 2

a Progression-free survival (PFS) in patients treated with non-bortezomib based therapies, without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve). b Overall survival (OS) in patients treated with treatments non- bortezomib based therapies without autologous transplantation (blue curve) and patients treated with bortezomib-based regimens and autologous transplantation (green curve)